ArticleRSC advances2025
Encapsulation of nanoparticles with Xe adsorption sites into MOFs for enhanced Xe/Kr separation.
Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Xenon (Xe) and krypton (Kr) are important gases with significant industrial and medical applications. Metal-organic frameworks (MOFs) are a promising class of sorbent materials for Xe/Kr separation. To enhance the Xe/Kr separation performance of MOFs, we develop a strategy to encapsulate Pt nanoparticles into MOFs to introduce strong Xe adsorption sites. Xe and Kr adsorption and separation studies show that Pt@UiO-66 exhibits 21% higher Xe uptake capacity and a 7% increase in Xe/Kr selectivity compared to UiO-66 due to the introduced Xe adsorption sites, despite the Brunauer-Emmett-Teller (BET) surface area decreasing. These findings have led to an 88% extension of column breakthrough time during Xe/Kr separation under identical conditions. We further demonstrate that this approach can be extended to other MOFs with potential for Xe/Kr separation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.